in

Clinical stage biopharmaceutical company: Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) was founded in 1990, formerly known as BioTime, Inc. (formerly AMEX:BTX TASE:BTX), changed to its current name on August 12, 2019, and headquartered in Alameda, California, USA , With 76 full-time employees, is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of degenerative disease products based on pluripotent stem cells and HyStem cell/drug delivery platform technology in the United States and Israel .

Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. (LCTX):

BioTime is a clinical-stage biotechnology company headquartered in Alameda, California. Its stock is traded on NYSE MKT under the ticker symbol BTX. BioTime is mainly engaged in research in the fields of aesthetics, ophthalmology, cell and drug delivery. The company is conducting clinical trials for dry age-related macular degeneration (dry AMD) and facial lipoatrophy for HIV patients.

1. BioTime’s main product candidates include: OpRegen, a retinal pigment epithelial cell replacement therapy, which is undergoing a phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration; Renevia, a facial beauty The product, used to treat HIV-related facial lipodystrophy, is undergoing key clinical trials.

2. BioTime has also developed HyStem, a hydrogel formula Previa, for the treatment of age-related facial lipoatrophy, and for the treatment of wounds, including partial and full-thickness wounds, ulcers, ruptures, surgical wounds and burns; ReGlyde, a HyStem product in the preclinical development stage, is used as a viscoelastic supplement device and as a platform for intraarticular drug delivery in osteoarthritis.

3. BioTime, through its subsidiary AgeX Therapeutics (spun off in November 2018), developed AGEX-BAT1, which is composed of brown adipocytes derived from pluripotent stem cells for the treatment of type 2 diabetes; AGEX-VASC1 Composition of vascular progenitor cells in myocardial ischemia; and induction of tissue regeneration, a systemic therapy that induces tissue regeneration from scars.

4. BioTime also sells GeneCards, a human gene database; MalaCards, a human disease database; and Hexend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, general 6% hydroxyethyl starch solution and crystals Solution.

BioTime, Inc. and Orbit Biomedical, Ltd. have a cooperation agreement.

On March 11, 2019, BioTime and Asterias Biotherapeutics reached a final merger agreement to create a leading cell therapy company.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

Canadian e-commerce software provider: Shopify Inc. (SHOP) (2006)

Chinese stocks: Sino-Global Shipping America (SINO) (2001)